35 results about "Signal transduction inhibitor" patented technology

The present invention relates to methods for treating cancer comprising utilizing a combination of signal transduction inhibitors. More specifically, the present invention relates to combinations of so called cell cycle inhibitors with mitogen stimulated kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide. The aforementioned combinations are useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and / or treatment of benign prostatic hyperplasia and / or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia / prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia / prostatic hypertrophy, as well as associated pharmaceutical compositions.

Methods and reagents are provided for determining the activation state of a signal transduction pathway signaling protein. There exists a need in the art for methods that can monitor the efficacy of a signal transduction inhibitor in a patient. Other needs exist for detecting and monitoring certain disease or disorders that are associated with aberrant activation of a signal transduction pathway signaling protein. The present assay provides a highly sensitive assay that is also useful in patient populations in which obtaining a large cellular sample is difficult, for example, neonates.

The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and cancer. The invention further relates to genes that are differentially expressed in tissue of cancer patients versus those of normal “healthy” tissue. Differentially expressed genes for the identification of patients which are likely to respond to chemotherapy are also provided. The present invention relates to methods for prognosis the prediction of therapeutic success in cancer therapy. In a preferred embodiment of the invention it relates to methods for prediction of therapeutic success of combinations of signal transduction inhibitors, therapeutic antibodies, radio- and chemotherapy. The methods of the invention are based on determination of expression levels of 48 human genes which are differentially expressed prior to the onset of anti-cancer chemotherapy. The methods and compositions of the invention are most useful in the investigation of advanced colorectal cancer, but are useful in the investigation of other types of cancer and therapies as well.

A medicament for treating a renal disease, comprising a therapeutically effective amount of an activin inhibitor as an active ingredient. Also, a method for treating a renal disease, comprising administering a therapeutically effective amount of an activin inhibitor to a patient suffering from renal disease is disclosed. The activin inhibitor may be follistatin, an anti-activin antibody, an inhibitor to activin receptor or an anti-activin receptor antibody, an inhibitor to signal transduction relating to activin receptor, an activin production inhibitor in kidney, and the like.

The invention relates to an improved process for preparing aminocrotonylamino-substituted quinazoline derivatives of general formula (I) wherein the groups Ra, Rb, Rc and Rd have the meanings given in the claims, as well as sulphonyl derivatives of formula (XIII) and the use thereof as synthesis components for preparing quinazolines of formula (I). The quinazoline derivatives of formula (I) are inhibitors of signal transduction mediated by tyrosinekinases and by the Epidermal Growth Factor-Receptor (EGF-R) and are therefore particularly suitable for the treatment of tumoral diseases.

The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and / or treatment of benign prostatic hyperplasia and / or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia / prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia / prostatic hypertrophy, as well as associated pharmaceutical compositions.

The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and / or treatment of benign prostatic hyperplasia and / or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia / prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia / prostatic hypertrophy, as well as associated pharmaceutical compositions.

A method for treating patients afflicted with cancer (including hematological malignancies) or viral infections, wherein the patients are under treatment or are to be treated with at least one anticancer or antiviral agent, and in particular (deoxy)nucleotide or (deoxy)nucleoside analog drugs, includes administering at least one small molecule inhibitor / activator (including ATP competitive inhibitors, signal transduction inhibitors / activators, protein kinase inhibitors / activators, and tyrosine kinase inhibitors / activators) in combination with the (deoxy) nucleotide or (deoxy)nucleoside analog, and wherein the small molecule inhibitor / activator is administered in sufficient amount to modulate deoxynucleotide or deoxynucleoside kinase activity (and in particular deoxycytidine kinase activity) to modulate activation of the (deoxy)nucleotide or (deoxy)nucleoside analog in vivo with a subsequent therapeutically beneficial anticancer or antiviral effect. The combined treatments together include a therapeutically effective amount.

Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.

The present invention relates to an RNA encoding a therapeutic protein, in particular a collagenase, growth factor, cytokine, receptor, chaperone or signal transduction inhibitor. In particular, the present invention relates to RNA suitable for treatment of wounds, specifically for promoting wound healing. The present invention concerns such RNA as well as pharmaceutical compositions and kits and combinations comprising the RNA. Furthermore, the present invention relates to the RNA, pharmaceutical compositions, kits as disclosed herein for use in the treatment of wounds, specifically for promoting wound healing.

The invention provides a culture medium for culturing mammary epithelial stem cells. The culture medium contains a TGF-beta inhibitor, B27 and / or N2, insulin, a receptor tyrosine kinase ligand, a Rock kinase inhibitor, a P38 signal transduction inhibitor, a bone morphogenetic protein inhibitor and an MST1 / 2 kinase inhibitor. The invention also provides a method for culturing cells by adopting the culture medium for the mammary epithelial stem cells, and application and methods of amplified cell populations or organoids obtained by adopting the culture method in drug screening, toxicity testing and regenerative medicine.

The invention provides novel means to inhibit the Mitogen Activated Protein Kinases (MAPKs) pathway activated by Ras / Raf complex using GILZ protein related compounds as inhibitors of Raf / Ras-mediated signal transduction. Pharmaceutical compositions containing such compounds are also disclosed.

Methods and pharmaceutical compositions for treating severe ischemic events including cerebral infarction, cardiac infarction, or pulmonary embolism, comprising a thrombolytic intervention including thrombolytic agents and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are disclosed.

An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since erbB1 and erbB2 are involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.

Provided herein are methods of treating beta-thalassemia by subcutaneous administration of about 0.8 mg / kg of an ActRII signaling inhibitor. Also provided herein are methods of adjusting the dose of the ActRII signaling inhibitor administered to the subject.

The present invention relates to methods of reducing proliferation of cells, enhancing apoptosis of cells or both in an individual in need thereof, comprising administering to the individual a combination of at least one farnesyl transferase inhibitor (FTI), such as an inhibitor of Ras function, and at least one signal transduction inhibitor (STI) in a therapeutically effective amount, wherein proliferation of cells is reduced and / or apoptosis of cells is enhanced in the individual. In one embodiment, the invention relates to a method of reducing proliferation of STI resistant cells, enhancing apoptosis of STI resistant cells, or both in an individual in need thereof, comprising administering to the individual a combination of at least one FTI and at least one STI in a therapeutically effective amount, wherein proliferation of STI resistant cells is reduced and / or apoptosis of STI resistant cells is enhanced in the individual. The present invention can be used to treat leukemia (e.g., CML) in an individual comprising administering to the individual a combination of at least one FTI and at least one STI in a therapeutically effective amount.

A method of selecting a subject having cancer for treatment with a Hedgehog signaling inhibitor by determining the level of expression of at least one biomarker in a biological sample derived from the subject.

A method of treating an individual comprising: evaluating the disease state of said individual through quantitative and / or qualitative assays; administering in amounts sufficient to treat said disease at least three agents wherein at least one agent is an inhibitor of the human epidermal receptor pathway, at least one agent is signal transduction inhibitor and at least one agent is an angiogenesis inhibitor and; reevaluating the disease state of said individual presenting through quantitative and / or qualitative assays. A composition comprising a first agent that is an inhibitor of the human epidermal receptor pathway, a second agent that is an angiogenesis inhibitor and a third agent that is an inhibitor of Akt wherein said first agent, second agent, third agent and combinations thereof are present in amounts that when administered to an individual in a diseased state are sufficient to treat said disease.

The present invention relates to a composition comprising at least one biological control agent. Furthermore, the present invention relates to the use of this composition as well as a method for reducing overall damage of plants and plant parts.

The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and / or treatment of benign prostatic hyperplasia and / or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia / prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia / prostatic hypertrophy, as well as associated pharmaceutical compositions.

The invention belongs to the field of biological medicine and relates to novel application of aspirin. The invention provides application of the aspirin in preparing anti-AIDs (acquired immune deficiency syndrome) drugs, and further provides an anti-AIDs drug composition containing the aspirin and application thereof. The anti-AIDs drug composition is suitable for HIV-1(human immunodeficiency virus-1) infection in every stage. Firstly, the effect of the aspirin is obvious, which is equivalent to congeneric clinical drug AZT (azidothymidine) which is used at present; secondly, the aspirin which is used as an NF-kappa B signal transduction inhibitor is not easy to generate drug resistance; thirdly, the aspirin has been in clinical use for many years, which is high in safety. Therefore, the invention provides a novel approach and a novel means for anti-HIV infection.

Identification of candidates for treatment and treatment of subjects experiencing cerebral ischemia wherein the treatment employs a thrombolytic or thrombectomy agent and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are determined by testing the blood of a patient for total S-100B or for S-100BB as a marker of blood brain barrier integrity.

The invention relates to a new application of phenothiazine compounds in pharmacy, wherein the phenothiazine compounds are selected from a compound represented by a formula (I), hydrates, solvates orreduced forms thereof; the invention particularly provides the application in preparation of a PD-1 signal transduction inhibitor. The phenothiazine compounds provided by the invention can inhibit thefunction of PD-1 and hinders the signal transduction of PD-1, so that the phenothiazine compounds can be used as a PD-1 signal transduction inhibitor. In-vitro experiments find that the compounds canrecover the functions of immune cells inhibited by PD-1, so that the functions of secreting cytokines and killing target cells of immune cells such as CTL and the like are improved, the immune function of an organism can be improved, and tumors can be effectively treated.